BL-B01D1 targets EGFR/HER3 on tumor cells, internalizes, and releases a topoisomerase I–inhibiting payload that causes DNA damage. DNA topoisomerase I is not the antibody-recognized target; killing depends on EGFR/HER3 binding (with possible bystander effect), not on Top1 expression itself.